Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Pulse Biosciences reported a quarterly loss of $0.29 per share, which was better than the Zacks Consensus Estimate of a loss of $0.31, but worse than a loss of $0.16 per share a year ago, indicating an earnings surprise of +6.45% [1] - The company generated revenues of $0.09 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 82.8%, compared to zero revenues a year ago [2] - The stock has underperformed, losing about 7.8% since the beginning of the year, while the S&P 500 gained 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $0.75 million, and for the current fiscal year, it is -$1.17 on revenues of $1.25 million [7] - The estimate revisions trend for Pulse Biosciences was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Pulse Biosciences belongs, is currently in the top 37% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, Teleflex, is expected to report quarterly earnings of $3.38 per share, reflecting a year-over-year change of -3.2%, with revenues expected to be $893.51 million, up 16.9% from the previous year [9][10]